Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer

  • Authors:
    • Masahide Ikeguchi
    • Nobuaki Kaibara
  • View Affiliations

  • Published online on: December 1, 2001     https://doi.org/10.3892/ijmm.8.6.661
  • Pages: 661-666
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Survivin is a member of the inhibitor of apoptosis protein (IAP) family. The expression of survivin has not been reported in differentiated normal tissues, but it has been observed in many cancerous tissues. Recent studies have revealed that survivin may correlate with the chemo-radio resistance of certain malignant cells. In the present study, the correlation between the occurrence of apoptosis and the level of expression of survivin messenger RNA (mRNA) was investigated in a gastric cancer cell line (MKN-45) and in patients with advanced gastric cancer during cisplatin (CDDP) treatment. In the gastric cancer cell line, the percentage of apoptotic cells (apoptotic index: AI) did not change after 48 h incubation with low-dose CDDP (1 μg/ml), whereas the AI explosively increased between 12 and 24 h treatment with high-dose CDDP (10 μg/ml). Relative levels of expression of survivin mRNA and survivin protein increased after low- and high-dose CDDP treatment. Survivin mRNA was not detected in normal gastric mucosas. Also, in 13 patients with advanced gastric cancer who underwent CDDP-based preoperative chemotherapy, survivin mRNA was detected in only 2 cases (15.4%). Survivin mRNA was observed in the resected tumor specimens of two cases. No significant correlation between survivin mRNA expression and the occurrence of apoptosis in resected tumors or between survivin mRNA expression and patient survival was observed. These findings indicate that survivin may play an important role for the chemoresistance of this cancer cell line. However, the clinical importance of survivin expression remains unclear in patients with gastric cancer.

Related Articles

Journal Cover

December 2001
Volume 8 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ikeguchi M and Ikeguchi M: Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 8: 661-666, 2001
APA
Ikeguchi, M., & Ikeguchi, M. (2001). Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. International Journal of Molecular Medicine, 8, 661-666. https://doi.org/10.3892/ijmm.8.6.661
MLA
Ikeguchi, M., Kaibara, N."Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer". International Journal of Molecular Medicine 8.6 (2001): 661-666.
Chicago
Ikeguchi, M., Kaibara, N."Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer". International Journal of Molecular Medicine 8, no. 6 (2001): 661-666. https://doi.org/10.3892/ijmm.8.6.661